Michal Wachterman is joining the pricing-intelligence startup Fetcherr Ltd, and will manage the company s operations in the United States. Wachterman has served for the past 15 years as Director of the United Airlines IT Department, and is part of a comprehensive expansion in the company, which is currently establishing a global business development system. Fetcherr’s system uses an artificial intelligence algorithm that it claims can provide usable insights on what the future holds for sales.
Fetcherr has added several senior executives recently as part of its extensive business development system, including the appointment of the former British Airways CEO and Chairman, Alex Cruz. Wachterman, who will be responsible for opening new markets and creating business opportunities in the U.S., is an IT manager with 30 years of experience in providing technical solutions in the field of aviation and tourism, and served in the past as the IT manager of United Airlines for revenue
শান্তা সিকিউরিটিজের নতুন প্রধান নির্বাহী কর্মকর্তা কাজী আসাদুজ্জামান sharebazarnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sharebazarnews.com Daily Mail and Mail on Sunday newspapers.
The Australian TGA approves key label updates to Buvidal® for treatment of opioid dependence
News provided by
Share this article
Share this article
LUND, Sweden, May 3, 2021 /PRNewswire/ Camurus AB (NASDAQ STO: CAMX) today announced that the Australian regulatory agency, the Therapeutic Goods Administration (TGA), has approved key label updates to Buvidal
® Weekly and Buvidal
The approval includes:
A new higher Buvidal Monthly 160 mg dose
Direct initiation onto Buvidal Weekly, removing the requirement to be stabilised on sublingual buprenorphine prior to commencing treatment with Buvidal
®
Changing the contraindications in pregnancy and lactation to precautions
In 2020 over 53,000 Australians received treatment for their opioid dependence, which represents a 4.7% increase on the previous year. This was the largest increase in treatment delivery in the past decade and has been attributed to the introduction of long-acting injectable buprenorphine treatment which has
The Australian TGA approves key label updates to Buvidal for treatment of opioid dependence Weekly and Buvidal
The approval includes:
A new higher Buvidal Monthly 160 mg dose
Direct initiation onto Buvidal Weekly, removing the requirement to be stabilised on sublingual buprenorphine prior to commencing treatment with Buvidal
Changing the contraindications in pregnancy and lactation to precautions
In 2020 over 53,000 Australians received treatment for their opioid dependence, which represents a 4.7% increase on the previous year. This was the largest increase in treatment delivery in the past decade and has been attributed to the introduction of long-acting injectable buprenorphine treatment which has increased treatment access and capacity.